EDAP Set For Long-Term Growth

  • The company offers an innovative device that produces non-invasive HIFA treatment for prostate cancer with other applications to follow.
  • Despite the pandemic and reimbursement which is yet to be settled, the company is still managing to sell these devices.
  • An increasing installed base will increase the stream of revenue from consumables.
  • The company isn’t bleeding cash and the shares are fairly cheap.

Source: EDAP Set For Long-Term Growth (NASDAQ:EDAP) | Seeking Alpha